We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

RYSAS:BISTReysas Tasimacilik ve Lojistik Ticaret Anonim Sirketi Analysis

Data as of 2026-03-16 - not real-time

TRY 17.39

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Reysas trades at TRY 17.39, comfortably above its 20‑day SMA (≈17.28) and the 50‑day SMA (≈17.93), suggesting a short‑term bullish bias, yet the MACD histogram remains negative and the signal line is bearish, hinting at weakening momentum. Volume is on a downtrend and volatility is elevated at over 54% for the past 30 days, amplifying price swings. On the fundamentals side, the company posts a negative profit margin (‑15%) and a trailing EPS of ‑5.42, with a massive debt load (≈TRY 7.9 bn) that dwarfs its cash (≈TRY 4.2 bn), resulting in a debt‑to‑equity ratio near 28. The DCF fair‑value estimate of roughly TRY 10.4 is well below the current price, indicating the stock is overvalued and the lack of any dividend further weakens its appeal.
Given the “Extreme Greed” market sentiment (Fear‑Greed Index 79.45) and a bullish trend direction, the upside potential is limited by deteriorating earnings, high leverage and a bearish technical divergence, making the near‑term outlook cautious.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price above short‑term moving averages but MACD bearish
  • Decreasing volume and high short‑term volatility
  • Negative earnings and high debt limiting upside

Medium Term

1–3 years
Neutral
Model confidence: 4/10

Key Factors

  • Continued earnings pressure and negative free cash flow
  • Valuation gap versus DCF fair value
  • Potential for sector‑specific headwinds in Turkish logistics

Long Term

> 3 years
Cautious
Model confidence: 6/10

Key Factors

  • Fundamental weakness: negative profit margin, high leverage
  • Overvaluation relative to intrinsic estimate
  • Lack of dividend and uncertain macro‑economic environment in Turkey

Key Metrics & Analysis

Financial Health

Revenue Growth-25.60%
Profit Margin-14.93%
ROE-3.52%
ROA5.60%
Debt/Equity27.95
P/B Ratio1.7
Op. Cash FlowTRY2.6B
Free Cash FlowTRY-3981193728
Industry P/E29.3

Technical Analysis

TrendBullish
RSI45.6
SupportTRY 16.60
ResistanceTRY 21.84
MA 20TRY 18.28
MA 50TRY 17.93
MA 200TRY 16.24
MACDBearish
VolumeDecreasing
Fear & Greed Index79.45

Valuation

Fair ValueTRY 10.44
GradeOvervalued
TypeValue

Risk Assessment

Beta0.27
Volatility54.56%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.